161 related articles for article (PubMed ID: 31493961)
1. Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019, 76:9-13.
Shi MJ; Meng XY; Chen CL; Dyrskjøt L; Radvanyi F; Prokunina-Olsson L; Bernard-Pierrot I
Eur Urol; 2020 Jan; 77(1):e26-e27. PubMed ID: 31493961
[No Abstract] [Full Text] [Related]
2. Re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019;76:9-13.
Yang A; Cannataro VL; Townsend JP
Eur Urol; 2020 Jan; 77(1):e24-e25. PubMed ID: 31474441
[No Abstract] [Full Text] [Related]
3. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer.
Shi MJ; Meng XY; Lamy P; Banday AR; Yang J; Moreno-Vega A; Chen CL; Dyrskjøt L; Bernard-Pierrot I; Prokunina-Olsson L; Radvanyi F
Eur Urol; 2019 Jul; 76(1):9-13. PubMed ID: 30975452
[TBL] [Abstract][Full Text] [Related]
4. Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4.
Kettunen K; Boström PJ; Taimen P
Eur Urol; 2019 Nov; 76(5):e137-e138. PubMed ID: 31420250
[No Abstract] [Full Text] [Related]
5. Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur Urol 2020;78:907-15: Linking FGFR3 Mutation Status and Luminal Papillary Subtype to Response to Cisplatin-based Chemotherapy in Bladder Cancer.
Roumiguie M; Contreras-Sanz A; Black PC
Eur Urol; 2021 Jun; 79(6):e182-e183. PubMed ID: 33838962
[No Abstract] [Full Text] [Related]
6. Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4-6.
Li R; Spiess PE; Gilbert SM; Necchi A
Eur Urol; 2019 Aug; 76(2):e34. PubMed ID: 31056228
[No Abstract] [Full Text] [Related]
7. Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
Vila-Reyes H; Joel DeCastro G; McKiernan JM
Eur Urol; 2021 Feb; 79(2):e54-e55. PubMed ID: 33248798
[No Abstract] [Full Text] [Related]
8. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
[TBL] [Abstract][Full Text] [Related]
9. Reply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-87.
Bayne CE; Williams -B; Chapin BF
Eur Urol; 2017 Feb; 71(2):e51. PubMed ID: 27461403
[No Abstract] [Full Text] [Related]
10. Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
Panebianco V; Del Giudice F; Narumi Y; Simone G; De Berardinis E; Catto JWF
Eur Urol; 2021 Feb; 79(2):e52-e53. PubMed ID: 33261940
[No Abstract] [Full Text] [Related]
11. Reply to Fredrik Liedberg, Pontus Eriksson, and Gottfrid Sjödahl's Letter to the Editor re: A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol;2020:533-7.
Meeks JJ; Dyrsjkøt L; Robertson AG
Eur Urol; 2020 Dec; 78(6):e230-e231. PubMed ID: 32994066
[No Abstract] [Full Text] [Related]
12. Reply to Xuefeng Liu's Letter to the Editor, re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4: Can Patient-derived Cancer Models Change the Costliest Cancer Type?
Kettunen K; Boström P; Taimen P
Eur Urol; 2020 Jan; 77(1):e23. PubMed ID: 31564578
[No Abstract] [Full Text] [Related]
13. Reply to Erik Rud and Eduard Baco's Letter to the Editor re: Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16-40.
Barentsz JO; Choyke PL; Cornud F; Haider MA; Macura KJ; Margolis D; Shtern F; Padhani AR; Tempany CM; Thoeny HC; Verma S; Weinreb JC
Eur Urol; 2016 Nov; 70(5):e137-e138. PubMed ID: 27130148
[No Abstract] [Full Text] [Related]
14. Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28.
Moschini M; Zaffuto E; Mattei A; Karakiewicz PI; Shariat SF
Eur Urol; 2019 Apr; 75(4):e98-e99. PubMed ID: 30503180
[No Abstract] [Full Text] [Related]
15. Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol 2019;76:260-1.
Bessa A; Maclennan S; Enting D; Bryan R; Häggström C; Van Hemelrijck M
Eur Urol; 2019 Aug; 76(2):e45-e46. PubMed ID: 31109813
[No Abstract] [Full Text] [Related]
16. Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65.
Choi W; McConkey D
Eur Urol; 2018 Apr; 73(4):e104-e105. PubMed ID: 29174465
[No Abstract] [Full Text] [Related]
17. Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
Carvalho FLF; Mossanen M; Van Allen EM; Mouw KW
Eur Urol; 2022 Nov; 82(5):e141-e142. PubMed ID: 35945087
[No Abstract] [Full Text] [Related]
18. Reply to Francesco Montorsi and Giorgio Gandaglia's Letter to the Editor re: Riccardo Autorino, Homayoun Zagar, Mirandolino B. Mariano, et al. Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-institutional Analysis. Eur Urol 2015;68:86-94; Re: Matthew Bultitude, Ben Challacombe. Simple Prostatectomy: A Step Too Far for Laparoscopy? Eur Urol 2015;68:95-6. Eur Urol 2015;68:e7-8.
Autorino R; Zargar H; Porpiglia F
Eur Urol; 2015 Jul; 68(1):e9-10. PubMed ID: 25666848
[No Abstract] [Full Text] [Related]
19. Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28: Radiation Therapy Versus Radical Prostatectomy: No Way Out Without a Randomized Trial.
Moschini M; Zaffuto E; Mattei A; Karakiewicz PI; Shariat SF
Eur Urol; 2019 Apr; 75(4):e95. PubMed ID: 30509762
[No Abstract] [Full Text] [Related]
20. Reply to Weigang Yan, Zhien Zhou, Hanzhong Li's Letter to the Editor re: Jeffrey J. Tosoian, Debasish Sundi, Bruce J. Trock, et al. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. Eur Urol 2016;69:576-81.
Tosoian JJ; Trock BJ; Ballentine Carter H; Mamawala M
Eur Urol; 2017 Jan; 71(1):e13. PubMed ID: 27311363
[No Abstract] [Full Text] [Related]
[Next] [New Search]
